Literature DB >> 23206447

Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications.

P Zhang1, X-K Liu, Z Chu, J C Ye, K-L Li, W-L Zhuang, D-J Yang, Y-F Jiang.   

Abstract

OBJECTIVE: To study the clinical significance of intercellular interleukin (IL)-33 in hepatocellular carcinoma (HCC).
METHODS: Using immunohistochemistry, this prospective study compared IL-33 protein levels in samples of HCC tissue and normal tissue adjacent to the tumour in 60 patients with HCC, and in normal liver tissue from six healthy controls. Interferon (IFN)-α, IFN-γ and IL-33 serum levels were also analysed by enzyme-linked immunosorbent assay in HCC 30 patients and 10 healthy controls. The level of IL-33 immunohistochemical staining was compared with the rate of lymph node metastasis in HCC patients.
RESULTS: IL-33 was strongly positive in the cytoplasm of hepatocytes. The median percentage of IL-33-positive tissue was higher in HCC than in normal liver tissue samples (adjacent to the tumour or from controls). Serum IFN-α, IFN-γ and IL-33 levels were higher in pre- and postoperative samples from HCC patients than in control samples, and in patients with metastasis compared with those without metastasis.
CONCLUSIONS: Increased IL-33 protein levels were observed in serum and liver tissue from HCC patients; IL-33 may be a useful biological marker for monitoring HCC growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23206447     DOI: 10.1177/030006051204000504

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  28 in total

1.  IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway.

Authors:  Xi-Xiang Yu; Zhe Hu; Xian Shen; Li-Yang Dong; Wei-Zhong Zhou; Wen-Hao Hu
Journal:  Dig Dis Sci       Date:  2015-02-06       Impact factor: 3.199

Review 2.  IL-33 in Tumor Immunity: Nothing to Sneeze At.

Authors:  Donye Dominguez; Yi Zhang; Bin Zhang
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

3.  Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.

Authors:  Pawel Sowa; Maciej Misiolek; Maciej Zielinski; Bogdan Mazur; Monika Adamczyk-Sowa
Journal:  Exp Biol Med (Maywood)       Date:  2018-05

4.  Interleukin-33 and ST2 Signaling in Tumor Microenvironment.

Authors:  Jaewoo Hong; Soohyun Kim; P Charles Lin
Journal:  J Interferon Cytokine Res       Date:  2018-09-25       Impact factor: 2.607

5.  Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.

Authors:  Shuixia Tan; Jing Zhao; Ziyu Sun; Shuangyi Cao; Kongyan Niu; Yedan Zhong; Han Wang; Linyu Shi; Heling Pan; Junhao Hu; Lihui Qian; Nan Liu; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

6.  Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment.

Authors:  Miho Akimoto; Riruke Maruyama; Hiroyuki Takamaru; Takahiro Ochiya; Keizo Takenaga
Journal:  Nat Commun       Date:  2016-11-24       Impact factor: 14.919

7.  The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes.

Authors:  Francesca Capone; Eliana Guerriero; Giovanni Colonna; Patrizia Maio; Alessandra Mangia; Raffaele Marfella; Giuseppe Paolisso; Francesco Izzo; Nicoletta Potenza; Luigi Tomeo; Giuseppe Castello; Susan Costantini
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

8.  Tristetraprolin inhibits gastric cancer progression through suppression of IL-33.

Authors:  Kaiyuan Deng; Hao Wang; Ting Shan; Yigang Chen; Hong Zhou; Qin Zhao; Jiazeng Xia
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

9.  Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma.

Authors:  Yan Yang; Jun-Bin Wang; Yu-Mei Li; Y U Zhao; Rui Wang; Qiong Wu; Rong-Sheng Zheng; Yu-Rong Ou
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

10.  An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer.

Authors:  Charlotte O'Donnell; Amr Mahmoud; Jonathan Keane; Carola Murphy; Declan White; Sinead Carey; Micheal O'Riordain; Michael W Bennett; Elizabeth Brint; Aileen Houston
Journal:  Br J Cancer       Date:  2015-12-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.